Spero Therapeutics (SPRO) Liabilities and Shareholders Equity (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $59.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 24.05% year-over-year to $59.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $244.2 million (down 48.4% YoY) and the FY2025 annual result came in at $68.9 million, down 37.65% from the prior year.
• Liabilities and Shareholders Equity fell to $59.0 million in Q1 2026, from $68.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $182.4 million in Q4 2023 to a low of $54.2 million in Q3 2025.
• A 5-year average of $105.0 million and a median of $107.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity soared 66.11% — and 2025, when it slumped 59.92%.
• Tracing SPRO's Liabilities and Shareholders Equity over 5 years: stood at $124.8 million in 2022, then surged by 46.14% to $182.4 million in 2023, then tumbled by 39.39% to $110.5 million in 2024, then sank by 37.65% to $68.9 million in 2025, then declined by 14.36% to $59.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $59.0 million (Q1 2026), $68.9 million (Q4 2025), and $54.2 million (Q3 2025), per Business Quant data.